Latest Breaking News On - Harbin medical university cancer hospital - Page 1 : comparemela.com
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain. Details of the presentations are as foll
Hong-kongShanghaiChinaLu-wangLiaoningSpainJapanMadridWuhanHubeiNanjingJiangsuTitle:
A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
Lead Author
Session:
Abstract Number:
About Savolitinib
Savolitinib is an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase which has been shown to function abnormally in many types of solid tumors promoting tumor growth, angiogenesis, and metastasis. Savolitinib has been studied in over 1,100 patients to date. In clinical studies, it has shown promising clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile.
ChinaShanghaiPekingBeijingHebeiJilinLin-shenGuangdongYanzhi-cuiFilip-jankuValld-hebronYuxian-bai